News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Akela Pharma Inc. Awarded Development Contract at its Akela Pharma Inc. Subsidiary


7/24/2008 3:09:38 PM

MONTREAL, July 24 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has been awarded a contract at its PharmaForm subsidiary located in Austin, Texas, to process validate and manufacture Phase III Registration Batches for Proellex(R), a drug product developed by Repros Therapeutics, Inc (NASDAQ: "RPRX").

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES